Sign in

NCT05929976Recruiting

InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort

Multi-National Nutritional Biobanking Program in Pediatric Oncology InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort

Source: ClinicalTrials.gov · Last updated 22 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-effects. Eligible patients must be between 3 years and 18 years of age at time of assent/consent, have newly diagnosed B- or T-cell acute lymphoblastic leukemia or mixed phenotype acute leukemia confirmed by pathology report, and must be receiving treatment at one of the participating centers. Patients receiving hematopoietic cell transplant will be excluded. Institutions were selected to ensure representation of several global health indicators related to nutritional status and wealth classification according to the World Bank. Data related to demographic variables (socioeconomic status, food security), lifestyle habits (diet, physical activity), nutritional anthropometrics (height, weight and arm anthropometry), and nutritional biological indices (stool and blood) will be collected at designated timepoints throughout treatment and one year after the end of treatment.

Status (registry)
Recruiting
Study type
Observational
Enrollment
4900 (estimated)
First submitted
15 Jun 2023
Start date
26 Oct 2022
Primary completion date
1 Oct 2029
Lead sponsor
Columbia University
NCT number
NCT05929976

What you commit to

  • Study type: Observational
  • Planned participants: 4900
  • From 26 Oct 2022 to the primary completion date, 1 Oct 2029
  • 8 sites in 6 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • \- Patients receiving hematopoietic cell transplant.

Who the study is looking for

  • Patients must be between 3 years and 18 years of age at time of assent/consent.
  • Patients must have newly diagnosed B- or T-cell ALL, or mixed phenotype acute leukemia confirmed by pathology report.
  • Patients must be receiving treatment at one of the participating centers.

Age in the registry: 3 years to 18 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (8)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital de Cancer Infanto Juvenil de Barretos
Coordinator of this site? Confirm its status
BarretosBrazilRecruiting
Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)
Coordinator of this site? Confirm its status
RecifeBrazilRecruiting
Instituto de Tratamento do Câncer Infantil (ITACI)
Coordinator of this site? Confirm its status
São PauloBrazilRecruiting
Unidad Nacional De Oncologia Pediatrica
Coordinator of this site? Confirm its status
Guatemala CityGuatemalaRecruiting
Hospital Escuela
Coordinator of this site? Confirm its status
TegucigalpaHondurasRecruiting
Post Graduate Institute of Medical Education and Research (PGIMER)
Coordinator of this site? Confirm its status
ChandigarhIndiaRecruiting
Muhumbili Hospital
Coordinator of this site? Confirm its status
Dar es SalaamTanzaniaRecruiting
Columbia University Irving Medical Center
Coordinator of this site? Confirm its status
New YorkUnited StatesActive, not recruiting

This page is information, not medical advice. Discuss any trial with your doctor.